The Trump administration’s confidential deals with pharmaceutical companies to lower U.S. drug prices include inducements to raise drug prices overseas and promise protection from President Donald Trump’s tariffs, according to documents shared with The Washington Post.
The Trump administration’s confidential deals with pharmaceutical companies to lower U.S. drug prices include inducements to raise drug prices overseas and promise protection from President Donald Trump’s tariffs, according to documents shared with The Washington Post.
